During the outbreak of the Covid-19 pandemic, we realized that Improdia’s test also provides a valuable community health tool to measure and manage clinical risk,
The Israeli diagnostics company Improdia has signed a cooperation agreement with Tel Aviv Sourasky Medical Center (Ichilov) to perform a large-scale clinical trial on diabetes
A Novel Biomarker SNX9 For Chronic Inflammation and associated Immunosuppression and a new regulator of T-Cell expression and receptor expression and function A new Improdias`
Prof. Dedi Meiri, a lecturer and researcher in the field of medical cannabis at the Technion Institute of Technology, Haifa, and head of its Laboratory
